Summary
Other Scenarios:
- TEVA - RHHBY
- TEVA - GSK
- RHHBY - ARNA
- GSK - ARNA
| Buyer: | Teva Pharmaceutical Industries Ltd (TEVA) | Last Price: | 41.81 | Market Cap.: | 39.32B |
|---|---|---|---|---|---|
| Target: | Arena Pharmaceuticals Inc (ARNA) | Last Price: | 6.36 | Market Cap.: | 928.32M |
Lines of Business Summary:
- Teva Pharmaceutical Industries Ltd (TEVA) competes in 1 industry and 506 product/service groups
- Arena Pharmaceuticals Inc (ARNA) competes in 1 industry and 10 product/service groups
- A combined entity will have 1% Product/Service Group overlap
- Teva Pharmaceutical Industries Ltd (TEVA) has 1 and Arena Pharmaceuticals Inc (ARNA) has 0 suppliers that rely on a material % of their business. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
731 |
Biopharmaceuticals |
|
|
334 |
|
Medical Devices |
|
177 | |
|
Outsourced Biomedical Services |
|
39 | |
|
Veterinary Products and Services |
|
8 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 449)
|
Target (Total: 10)
|
Buyer
|
Targetn/a |
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 28)
|
Target (Total: 0)n/a |
Buyer (Total: 6)
|
Target (Total: 5)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 42,000 | 351 |
| Revenue Per Employee | 425,978.0 | 37,241.6 |
| Total Revenue | 5,102.0 | 2.2 |
| Total Expenses | 4,174.0 | 21.8 |
Other Revenue
|
n/a | n/a |
|
Cost of Revenue
|
2,493.0 | 0.8 |
|
SG&A Expense
|
1,228.0 | 6.4 |
|
Research & Development
|
292.0 | 14.5 |
|
Other Operating Expense
|
n/a | n/a |
|
Operating Income
|
928.0 | -19.6 |
|
Unusual Income
|
149.0 | 1.7 |
|
LT Debt to Capital
|
30.59 | n/a |
|
Fwd P/E
|
7.52 | -8.51 |
|
Fwd P/Rev
|
1.83 | 10.81 |
| Book Value | 23,051.0 | 44.8 |
|
Curr Portion of LTD/Cap Lease
|
531.0 | n/a |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Sector Pure-Play ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva?s active pharmaceutical ingredient (API) business provides vertical integration to Teva?s own pharmaceutical production. manufactures and sells generic pharmaceutical products in a range of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. As December 31, 2010, it had direct operations in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites in 19 countries, 28 pharmaceutical research and development (R&D) centers and 21 API manufacturing sites. During the year ended December 31, 2010, it acquired Laboratoire Theramex, Corporacion Infarmasa (Infarmasa) and Merckle ratiopharm Group (ratiopharm).
Target
Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena?s advanced drug candidate is lorcaserin hydrochloride, for weight management, which has completed two pivotal Phase III clinical trials for lorcaserin. The Company?s wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc., rights to commercialize lorcaserin in the United States and its territories and possessions subject to Food and Drug Administration approval of the lorcaserin new drug application. Its research and development programs also include APD597, APD916, APD791 and APD125, all of which are oral drug candidates.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
51.39 | 40.73 |
|
Operating Margin %
|
16.4 | -703.07 |
|
Quick Ratio
|
0.53 | 6.21 |
|
Current Ratio
|
1.1 | 4.2 |
|
Coverage Ratio
|
n/a | n/a |
| Total Assets | 50,470.0 | 187.8 |
| Return on Equity % | 50.6 | -855.78 |
| Return on Assets % | 23.11 | -204.27 |
|
Cash+ ST Inv. Per Share
|
1.25 | 0.54 |
| Total Debt | 14,522.0 | 88.0 |
| Total Debt to Equity % | 63 | 196.21 |
| Total Debt to Tangible Equity % | n/a | 260.26 |
|
Debt to Asset %
|
28.77 | 46.83 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit the inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Adjunctive Treatments |
|
|
|
Antihistamines/Antiserotonins
Therapeutics that assist the primary treatment of a life-threatening systemic allergic reaction resulting from secondary or subsequent exposure to a foreign substance by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Upper Respiratory |
|
|
|
Anticholinergic Agents
Therapeutics that treat allergic reactions by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the risk of chest pains by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat congestive heart failure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the ineffective pumping of the heart by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat the ineffective pumping of the heart by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat/prevent myocardial infarction by blocking the angiotensin II receptor, which results in dilated blood vessels.
Buyer Products:
|
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Blockers/Beta Blockers
Therapeutics that treat high blood pressure by blocking alpha and beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the dopamine receptors of the heart muscle.
Buyer Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Hypotension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat low blood pressure by stimulating alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Buyer Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that treat hypertension by increasing level of nitric oxide that help to dilate blood vessels.
Buyer Products:
|
|
|
|
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that reduce the risk of stroke by reducing high blood pressure through blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat damage to nerve cells of the brain by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Platelet Aggregation Inhibitors |
|
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
|
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat hair loss by dilating blood vessels.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Buyer Products:
|
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Buyer Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gall Bladder Disorders |
|
|
|
Cholelithiasis (Gallstones) |
|
|
|
Anticholelithic Agents
Therapeutics that treat gall stones by decreasing the liver's cholesterol synthesis and secretion.
Buyer Products:
|
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Ulcer Adhering Agents
Therapeutics that treat peptic ulcers by binding to it and protecting it from further damage.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
Antisecretory Agents
Therapeutics that treat peptic ulcers by preventing the secretion of acid.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Buyer Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat Esophagitis by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroparesis |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Impacted Bowels |
|
|
|
Hyperosmotic Agents
Therapeutics that treat constipation by causing fluid overload, which in turn induces liquid stool within a short period of time.
Buyer Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Buyer Products:
|
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation associated with ulcerative colitis by preventing the accumulation of inflammatory cells like leukocytes and macrophages to the inflammation site.
Buyer Products:
|
|
|
|
Intestinal Intubation |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Stomatognathic Disorders |
|
|
|
Toothaches |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat toothache by numbing a localized area.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.
Buyer Products:
|
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside/Nucleotide Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Central Diabetes Insipidus |
|
|
|
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat hypertension by regulating the blood vessel dilation.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes |
|
|
|
Immunomodulators
Therapeutics that treat Insulin Dependent Diabetes Mellitus by modulating the immune response that causes the destruction of insulin producing beta cells.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Buyer Products:
|
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Buyer Products:
|
|
|
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that control high blood sugar by stimulating the release of insulin as well as sensitizing organs to insulin.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Non-Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Buyer Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Dexamethasones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Prednisones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Carnitine Deficiency |
|
|
|
Fatty Acid Transporters
Therapeutics that treat the depletion of long-chain fatty acids in the mitochondrial matrix by increasing carnitine level in the plasma, which facilitate the entry of long-chain fatty acids into the mitochondria.
Buyer Products:
|
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce cholesterol levels by reducing the levels of low-density lipoproteins (LDL) and increasing levels of high-density lipoproteins (HDL).
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that treat hypercholesterolemia by reducing the levels of very low-density lipoprotein and increasing levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Calcimimetic Agents
Therapeutics that treat hyperparathyroidism by decreasing parathyroid hormone levels, which may provide effective reduction of calcium levels.
Buyer Products:
|
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Somatostatin Analogs
Therapeutics that prevents the secretion of growth hormones.
Buyer Products:
|
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Buyer Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Buyer Products:
|
|
|
|
Menopause |
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercalcemia |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat a disorder characterized by excessive calcium levels by inhibiting the resorption of bone.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that treat hypercholesterolemia by reducing the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increasing
levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that bind blood phosphorous.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Buyer Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Buyer Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Buyer Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of white blood cells.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Discoid (DLE) |
|
|
|
Immunosuppressants
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques using a steroidal compound.
Buyer Products:
|
|
|
|
Systemic (SLE) |
|
|
|
Anti-dsDNA Inhibitors
Therapeutics that treat systemic lupus by selectively reducing antibodies to double-stranded DNA (dsDNA).
Buyer Products:
|
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Oxazolidinones
Therapeutics that treat a wide variety of infections by inhibiting early initiation of bacterial protein synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Pseudominic Acids
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and RNA synthesis.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gingivitis |
|
|
|
Chlorhexidines
Therapeutics that treat inflammation of the gums by causing leakage in bacterial cell walls.
Buyer Products:
|
|
|
|
Periodontitis |
|
|
|
Tetracyclines
Therapeutics that treat bacterial infections of the gums, teeth, and underlying bone by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone/Joint Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat bacterial infections manifested in the bones or joints by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Conjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the clear membrane outside the eye preventing the mast cell release of histamine.
Buyer Products:
|
|
|
|
Keratitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea caused by bacterial infection by inhibiting the release of histamine and leukotrienes from mast cells.
Buyer Products:
|
|
|
|
Keratoconjunctivitis |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat inflammation of the cornea and the clear membrane outside the eye caused by bacterial infection by blocking the release of histamines from mast cells.
Buyer Products:
|
|
|
|
Ocular Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Pharyngitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the cone shaped cavity at the back of the mouth caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Pneumonia |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat infections of the air passage caused by a wide variety of bacteria.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Tonsilitis |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat inflammation of the lymphoid tissue on either side of the throat caused by bacterial infection by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Buyer Products:
|
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.
Buyer Products:
|
|
|
|
Helminthic |
|
|
|
Ascariasis (Roundworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm.
Buyer Products:
|
|
|
|
Enterobiasis (Pinworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm. itching.
Buyer Products:
|
|
|
|
Hookworms |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the intestines.
Buyer Products:
|
|
|
|
Trichuriasis (Whipworms) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat parasitic infections characterized by large worms attached to the lining of the large intestine.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Candidiasis |
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the skin caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Tinea Barbae |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Tinea Capitis |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the groin and perineum by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Pedis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.
Buyer Products:
|
|
|
|
Tinea Unquium |
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Tinea Versicolor |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the secretory lining of the tissues caused by a yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pharynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the mucosa caused by yeast by binding to sterols on the fungal cell membrane which results in the loss of potassium and other small molecules from the cell.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.
Buyer Products:
|
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Nucleoside/Nucleotide Analogs
Therapeutics that treat hepatitis by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Viral |
|
|
|
Single Target |
|
|
|
Adenoviruses
Therapeutics that prevent or treat viral infections which commonly cause upper respiratory infections, such as common cold.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active re-absorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Buyer Products:
|
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Buyer Products:
|
|
|
|
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists
Therapeutics that treat the disorders involving the progressive degeneration and death of brain cells by preventing the actions of an amino acid neurotransmitter, N-Methyl-D-Aspartate.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat simple partial seizures by preventing the uptake of gamma-aminobutyric acid which prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of sodium into nerve cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat Grand Mal Seizures by preventing the entrance of sodium into nerve cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Buyer Products:
|
|
|
|
Status Epilepticus |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Chronic |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation by preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Tension Type |
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons as well as decreasing pain by inhibiting the production of prostaglandins.
Buyer Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular headaches by attaching to specific receptors and mimicking the action of serotonin.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that prevent migraines by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation, as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Buyer Products:
|
|
|
|
Trigeminal Neuralgia (Tic Douloureux) |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat trigeminal Neuralgia by inhibiting the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Buyer Products:
|
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the degradation of neurotransmitters.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by relaxing motor muscles and relieving pain.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by preventing the degradation of neurotransmitters.
Buyer Products:
|
|
|
|
Restless Leg Syndrome |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat Restless Leg Syndrome by stimulating dopamine activity.
Buyer Products:
|
|
|
|
Tourette`s Syndrome |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat the disorder involving uncontrolled verbal outbursts, ticks and facial expressions by blocking dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat obsessive compulsive disorder by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat panic disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD) by stimulating the adrenergic receptors, which cause nervous system stimulation.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat attention deficit disorder by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.
Buyer Products:
|
|
|
|
Enuresis (Bedwetting) |
|
|
|
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.
Buyer Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat bipolar disorders by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat depression by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat depression by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists/Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin as well as blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Buyer Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Excessive Daytime Sleepiness (EDS) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat excessive daytime sleepiness (EDS) by stimulating the adrenergic receptors, which cause nervous system stimulation.
Buyer Products:
|
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Narcolepsy |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Induction/Cervical Ripening |
|
|
|
Oxytocic Agents
Therapeutics that induce contractions by increasing the levels of intracellular calcium in the uterine smooth muscle thus mimicking uterine contractions and transiently impeding uterine blood flow.
Buyer Products:
|
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Buyer Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometrial Hyperplasia |
|
|
|
Progestins
Therapeutics that treat a disorder involving the benign proliferation of cells lining the uterus (endometrium) by increasing progesterone levels in the body.
Buyer Products:
|
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Infertility |
|
|
|
Hormonal Treatments |
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Buyer Products:
|
|
|
|
Progestins
Therapeutics that treat female disorders characterized by the inability to achieve pregnancy or carry a pregnancy to term by increasing progesterone level in the body to induce uteran conditions favorable to conception and pregnancy.
Buyer Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat abnormal puberty by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage breast cancers by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Buyer Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
|
Estrogen Synthesis Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting the conversion of adrenal androgens to estrogen in peripheral tissues.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat breast cancer by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Malignant Melanoma |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Malignant Melanoma by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Buyer Products:
|
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancers of keratinizing epidermal cells by interacting with DNA.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage colorectal cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Buyer Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Buyer Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the stomach by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage primary tumors of the pancreas by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Nitrosoureas
Therapeutics that can cross the blood-brain barrier to treat and manage pancreatic cancers by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage pancreatic cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage metastatic pancreatic cancer by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Endocrinology |
|
|
|
Carcinoid Tumors |
|
|
|
Palliative Agents |
|
|
|
Somatostatin Analogs
Therapeutics that treat and manage a serotonin secreting neoplasm known as a carcinoid tumor by inhibiting the secretion of growth hormone which allows the tumor to grow rapidly.
Buyer Products:
|
|
|
|
Parathyroid Gland |
|
|
|
Palliative Agents |
|
|
|
Calcimimetic Agents
Therapeutics that treat hypercalcemia (elevated calcium levels in the blood) by decreasing parathyroid hormone levels.
Buyer Products:
|
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the thyroid gland by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the head and neck by interacting with DNA.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Lymphocytic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics isolated principally from microorganisms that treat rapidly progressing cancers of lymphocytic cells by interacting with DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Lymphocytic (CLL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage slowly progressing cancers of lymphocytic cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.
Buyer Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Erythroleukemic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Monocytic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myeloblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage rapidly progressing cancers of myelogenous cells by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Promyelocytic (APL) |
|
|
|
DNA Fragmenting Agents
Therapeutics that treat leukemia by breaking DNA, resulting in the death of cancer cells.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Myeloblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of immature myeloid cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Myelogenous (CML) |
|
|
|
Mcl-1 Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by inhibiting Mcl-1 protein synthesis, leading to cancer cell death (apoptosis).
Buyer Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Alkylating Agents |
|
|
|
Carbazines
Therapeutics that treat Hodgkin's Disease by inhibiting RNA and DNA synthesis through the formation of carbonium ions.
Buyer Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA.
Buyer Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphomas of B-cells and T-cells by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat lymphomas of B-cells and T-cells by interacting with DNA.
Buyer Products:
|
|
|
|
Stem Cell Therapy
Adult stem cells obtained from adult patients to treat hematological cancers.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Osteosarcoma |
|
|
|
Palliative Agents |
|
|
|
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Osteolytic Bone Metastases |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Neuroblastoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a and manage cancer of primitive ganglion cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.
Buyer Products:
|
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Cervical Cancer |
|
|
|
Localized |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary malignant tumors of the cervix by interacting with DNA.
Buyer Products:
|
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage tumors of the kidney by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage ovarian cancer by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Germ Cell Tumors |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage ovarian cancer by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers by interacting with DNA and inhibiting cell division but are not curative.
Buyer Products:
|
|
|
|
Penile Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the squamous cells of the penis by interacting with DNA.
Buyer Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.
Buyer Products:
|
|
|
|
Antisense Agents
Therapeutics that treat metastatic prostate cancer by targeting specific messenger-RNA and thereby inhibiting the production of specific proteins.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat and manage prostate cancer by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations but are not curative.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.
Buyer Products:
|
|
|
|
Testicular Cancer |
|
|
|
Localized |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage primary tumors of the testes by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat primary tumors of the testes by interacting with DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage testicular cancers that have spread beyond their original tumor site by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Papillocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage mushroom shaped tumors that arise from the inner lining of the bladder by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Transitional Cell Carcinoma |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancers arising from the lining of the bladder by interacting with DNA and inhibiting cell division.
Buyer Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers arising from the lining of the bladder by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Vulvar Cancer |
|
|
|
Squamous Cell Carcinoma |
|
|
|
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers that arise from skin cells of the external female genitalia by interacting with DNA.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Glaucoma |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Buyer Products:
|
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Buyer Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.
Buyer Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that decrease the formation and increase the outflow of the fluid of the eye.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Buyer Products:
|
|
|
|
Primary |
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Buyer Products:
|
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Buyer Products:
|
|
|
|
Local |
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of sodium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat pain by inhibiting the reuptake of GABA, which increases the levels of GABA in the synapses.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially, as well as prevent inflammation by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat pain by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.
Buyer Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Bacterial Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Agonists/Anticholinergic Agents
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine and by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Buyer Products:
|
|
|
|
Emphysema |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Antiserotonins
Therapeutics that inhibit inflammation by blocking the action of histamines and serotonins on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
|
|
|
|
Decongestants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Complications |
|
|
|
Ischemia |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent post surgical nausea and vomiting through a combination of blocking neurotransmitters and gastrointestinal movement stimulants.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Seizures |
|
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Heavy Metal Poisoning |
|
|
|
Chelating Agents |
|
|
|
Iron
Therapeutics that form chemical complexes with iron and are subsequently excreted.
Buyer Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Antihistamines
Therapeutics that treat alcohol withdrawal by blocking the H2 receptors and thus the effects of histamines.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Opioid Analgesics
Therapeutics that treat narcotic withdrawal by providing the body with a milder opioid substitute.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Bone Marrow |
|
|
|
Complications |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cells called granulocytes.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the breakdown of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that increase blood flow in the penis by dilating blood vessels.
Buyer Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Precocious |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat puberty disorders by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Cystitis |
|
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Buyer Products:
|
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Hyperparathyroidism |
|
|
|
Calcimimetic Agents
Therapeutics that treat hyperparathyroidism by decreasing parathyroid hormone levels, which may provide effective reduction of calcium levels.
Buyer Products:
|
|
|
|
Vitamin D Analogs
Therapeutics that provide the body with vitamin D like substances that help regulate the levels of calcium and phosphate in the blood.
Buyer Products:
|
|
|
|
Hyperphosphatemia |
|
|
|
Phosphate Binding Agents
Therapeutics that treat abnormal levels of phosphate in the blood by binding to excess phosphate groups.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat diabetes induced kidney diseases by inhibiting a certain enzyme necessary for regulation of blood pressure.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disease by blocking the angiotensin II receptor.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Anorexia (Appetite Loss) |
|
|
|
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.
Buyer Products:
|
|
|
|
Cachexia |
|
|
|
Progestins
Therapeutics that treat cachexia by providing female hormones.
Buyer Products:
|
|
|
|
Obesity |
|
|
|
Selective Serotonin Receptor Agonists
Therapeutics that treat obesity by stimulating the receptor that binds with the neurotransmitter serotonin involved in satiety and the metabolic rate regulation.
Target Products:
|
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Wound Management |
|
|
|
Burns |
|
|
|
Maintenance |
|
|
|
Tissue (Skin) Removal |
|
|
|
Debriding Agents
Therapeutics that treat skin injuries caused by fire or excessive heat by removing dead skin from the wound by catalyzing the breakdown of collagen.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Buyer Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Biopharmaceutical OEM |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Buyer Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
|
|
Drug Delivery Technology |
|
|
|
Oral Delivery |
|
|
|
Molecular Complex
Drug Delivery Technologies used to deliver drugs using a substance with the drugs embedded in it.
Buyer Products:
|
|
|
|
Transmucosal |
|
|
|
Drug Matrix
Drug Delivery Technologies used to deliver drugs using a substance with the drugs embedded in it.
Buyer Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
GlaxoSmithKline PLC
|
|
n/a | 115,869.873 | 15.41 | 11.55 | 3.65 | 2.56 | n/a | |
|
Athersys Inc
|
|
n/a | 34.549 | n/a | -2.36 | 3.34 | 3.38 | 4.73 | |
| Buyer | |||||||||
|
Novartis SA
|
|
n/a | 145,820.038 | 16.87 | 10.02 | 2.47 | 2.53 | 104.31 | |
|
Merck & Co Inc
|
|
n/a | 117,162.710 | 16.89 | 10.05 | 2.43 | 2.51 | 12.07 | |
|
GlaxoSmithKline PLC
|
|
n/a | 115,869.873 | 15.41 | 11.55 | 3.65 | 2.56 | n/a | |
|
Amgen Inc
|
|
n/a | 65,407.189 | 17.61 | 11.59 | 4.11 | 3.96 | 19.77 | |
|
Astrazeneca PLC
|
|
n/a | 58,543.357 | 7.02 | 7.04 | 1.79 | 2.01 | 94.73 | |
|
Gilead Sciences Inc
|
|
n/a | 39,992.232 | 15.51 | 14.94 | 4.57 | 4.31 | n/a | |
|
Biogen IDEC Inc
|
|
n/a | 33,158.436 | 26.97 | 21.87 | 6.45 | 6.07 | 9.95 | |
|
Allergan Inc
|
|
n/a | 28,589.381 | 28.44 | 22.21 | 5.16 | 4.87 | 12.90 | |
|
Covidien PLC
|
|
n/a | 27,247.823 | 13.91 | 12.70 | 2.30 | 2.27 | n/a | |
|
Shire PLC
|
|
n/a | 18,430.664 | 10.44 | 15.62 | 4.32 | 3.76 | 185.42 | |
|
Watson Pharmaceuticals Inc
|
|
n/a | 9,755.209 | 35.99 | 12.57 | 1.86 | 1.76 | 401.45 | |
|
Perrigo Co
|
|
n/a | 9,429.142 | 25.35 | 20.33 | 3.10 | 2.91 | 50.27 | |
|
Elan Corporation PLC
|
|
n/a | 7,863.375 | 17.28 | -668.50 | 6.44 | 6.41 | 15.69 | |
|
Hospira Inc
|
|
n/a | 5,496.746 | n/a | 15.85 | 1.37 | 1.38 | 3.42 | |
|
Dr Reddy'S Laboratories Ltd
|
|
n/a | 5,185.959 | 0.62 | 16.20 | 0.10 | n/a | n/a | |
|
Endo Pharmaceuticals Holdings Inc
|
|
n/a | 3,911.521 | 98.59 | 6.58 | 1.37 | 1.21 | n/a | |
|
Salix Pharmaceuticals Ltd
|
|
n/a | 3,030.334 | 30.86 | 20.58 | 5.00 | 4.01 | 6.38 | |
|
Cubist Pharmaceuticals Inc
|
|
n/a | 2,585.285 | 70.42 | 25.03 | 3.23 | 2.78 | 3.02 | |
| Target | |||||||||
|
Roche Holding AG
|
|
n/a | 145,117.557 | 25.19 | 10.28 | 2.12 | 3.03 | n/a | |
|
GlaxoSmithKline PLC
|
|
n/a | 115,869.873 | 15.41 | 11.55 | 3.65 | 2.56 | n/a | |
|
Vivus Inc
|
|
n/a | 2,194.846 | n/a | -38.46 | n/a | 27.44 | 6.74 | |
|
Orexigen Therapeutics Inc
|
|
n/a | 191.858 | n/a | -4.04 | 55.96 | 45.25 | 2.11 | |
|
Athersys Inc
|
|
n/a | 34.549 | n/a | -2.36 | 3.34 | 3.38 | 4.73 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Antares Pharma Inc
|
|
44.00% | 319.079 | n/a | -104.33 | 16.15 | 12.75 | 10.63 | |
|
3M Co
|
|
n/a | 61,538.031 | 14.38 | 13.57 | 2.07 | 2.01 | 8.03 | |
|
Astrazeneca PLC
|
|
n/a | 58,543.357 | 7.02 | 7.04 | 1.79 | 2.01 | 94.73 | |
|
Shire PLC
|
|
n/a | 18,430.664 | 10.44 | 15.62 | 4.32 | 3.76 | 185.42 | |
|
Valeant Pharmaceuticals International Inc
|
|
n/a | 15,932.235 | 121.08 | 12.08 | 5.78 | 4.57 | n/a | |
|
Perrigo Co
|
|
n/a | 9,429.142 | 25.35 | 20.33 | 3.10 | 2.91 | 50.27 | |
|
Human Genome Sciences Inc
|
|
n/a | 2,802.834 | n/a | -9.64 | 18.50 | 12.14 | 7.44 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,493.323 | 28.17 | 10.47 | 1.55 | 1.37 | n/a | |
|
Impax Laboratories Inc
|
|
n/a | 1,446.233 | 22.40 | 12.36 | 2.71 | 2.28 | 2.62 | |
|
Compugen Ltd
|
|
n/a | 138.550 | n/a | n/a | n/a | n/a | 7.08 | |
|
OncoGenex Pharmaceuticals Inc
|
|
n/a | 126.237 | n/a | -5.99 | 22.49 | 8.37 | 1.62 | |
|
Codexis Inc
|
|
n/a | 117.769 | n/a | -6.22 | 0.95 | 0.92 | 1.42 | |
|
Savient Pharmaceuticals Inc
|
|
n/a | 111.381 | n/a | -0.90 | 9.43 | 4.65 | n/a | |
|
CEL-SCI Corp (New)
|
|
n/a | 108.505 | n/a | n/a | 365.16 | n/a | 18.53 | |
|
Biosante Pharmaceuticals Inc
|
|
n/a | 49.503 | n/a | -1.68 | 101.37 | 56.36 | 1.30 | |
|
Rexahn Pharmaceuticals Inc
|
|
n/a | 42.857 | n/a | n/a | 1,151.47 | n/a | 4.00 | |
|
Skyepharma PLC
|
|
n/a | 31.126 | n/a | n/a | 0.37 | n/a | n/a | |
|
Rosetta Genomics Ltd
|
|
n/a | 1.215 | n/a | n/a | 11.78 | n/a | n/a | |
|
Autoimmune Inc
|
|
n/a | 0.039 | n/a | n/a | 0.06 | n/a | 0.00 | |
|
Active Biotech AB
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Acino Holding AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Evotec AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Gerresheimer AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Acusphere Inc
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Alkermes PLC
|
|
n/a | n/a | n/a | -61.93 | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Watson Pharmaceuticals Inc
|
|
n/a | 9,755.209 | 35.99 | 12.57 | 1.86 | 1.76 | 401.45 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,493.323 | 28.17 | 10.47 | 1.55 | 1.37 | n/a | |
|
Medicines Co
|
|
n/a | 1,165.046 | 5.19 | 19.87 | 1.37 | 2.15 | 2.99 | |
|
Paladin Labs Inc
|
|
n/a | 861.026 | 16.95 | n/a | 6.04 | n/a | 2.78 | |
|
Transcept Pharmaceuticals Inc
|
|
n/a | 110.886 | n/a | -4.54 | 11.09 | 10.43 | 2.05 | |
|
H. Lundbeck A/S
|
|
n/a | n/a | n/a | 10.69 | n/a | n/a | n/a | |
| Target | |||||||||
|
Johnson & Johnson
|
|
n/a | 176,314.376 | 10.12 | 12.61 | 1.55 | 2.65 | n/a | |
|
GlaxoSmithKline PLC
|
|
n/a | 115,869.873 | 15.41 | 11.55 | 3.65 | 2.56 | n/a | |
|
Eisai Co Ltd
|
|
n/a | 11,889.371 | 0.33 | 16.79 | 0.03 | 1.43 | 0.08 | |
|
TaiGen Biotechnology Co., Ltd
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Siegfried Holding SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Procter & Gamble Co
|
|
n/a | 174,977.866 | 13.90 | 16.62 | 1.65 | 2.09 | n/a | |
|
Novo-Nordisk A/S (vormals Novo Industri A/S)
|
|
n/a | 68,939.618 | 11.02 | 23.08 | 1.69 | 5.08 | 1.92 | |
|
3M Co
|
|
n/a | 61,538.031 | 14.38 | 13.57 | 2.07 | 2.01 | 8.03 | |
|
Shire PLC
|
|
n/a | 18,430.664 | 10.44 | 15.62 | 4.32 | 3.76 | 185.42 | |
|
Watson Pharmaceuticals Inc
|
|
n/a | 9,755.209 | 35.99 | 12.57 | 1.86 | 1.76 | 401.45 | |
|
Perrigo Co
|
|
n/a | 9,429.142 | 25.35 | 20.33 | 3.10 | 2.91 | 50.27 | |
|
Human Genome Sciences Inc
|
|
n/a | 2,802.834 | n/a | -9.64 | 18.50 | 12.14 | 7.44 | |
|
Myriad Genetics Inc
|
|
n/a | 2,203.715 | 27.51 | 19.81 | 4.68 | 4.45 | 3.80 | |
|
Par Pharmaceutical Cos Inc
|
|
n/a | 1,493.323 | 28.17 | 10.47 | 1.55 | 1.37 | n/a | |
|
Impax Laboratories Inc
|
|
n/a | 1,446.233 | 22.40 | 12.36 | 2.71 | 2.28 | 2.62 | |
|
Medicines Co
|
|
n/a | 1,165.046 | 5.19 | 19.87 | 1.37 | 2.15 | 2.99 | |
|
Genomic Health Inc
|
|
n/a | 923.990 | 113.05 | n/a | 4.30 | 3.72 | 7.54 | |
|
Paladin Labs Inc
|
|
n/a | 861.026 | 16.95 | n/a | 6.04 | n/a | 2.78 | |
|
Protalix BioTherapeutics Inc
|
|
n/a | 578.550 | n/a | 86.25 | 833.90 | 19.81 | n/a | |
|
Antares Pharma Inc
|
|
n/a | 319.079 | n/a | -104.33 | 16.15 | 12.75 | 10.63 | |
|
Biotime Inc
|
|
n/a | 182.771 | n/a | n/a | 27.03 | n/a | 18.23 | |
|
Compugen Ltd
|
|
n/a | 138.550 | n/a | n/a | n/a | n/a | 7.08 | |
|
OncoGenex Pharmaceuticals Inc
|
|
n/a | 126.237 | n/a | -5.99 | 22.49 | 8.37 | 1.62 | |
|
Codexis Inc
|
|
n/a | 117.769 | n/a | -6.22 | 0.95 | 0.92 | 1.42 | |
|
Savient Pharmaceuticals Inc
|
|
n/a | 111.381 | n/a | -0.90 | 9.43 | 4.65 | n/a | |
|
Transcept Pharmaceuticals Inc
|
|
n/a | 110.886 | n/a | -4.54 | 11.09 | 10.43 | 2.05 | |
|
CEL-SCI Corp (New)
|
|
n/a | 108.505 | n/a | n/a | 365.16 | n/a | 18.53 | |
|
Insmed Inc
|
|
n/a | 76.983 | n/a | -2.36 | 27.33 | 1.06 | 1.10 | |
| Target | |||||||||
|
Eisai Co Ltd
|
|
n/a | 11,889.371 | 0.33 | 16.79 | 0.03 | 1.43 | 0.08 | |
|
GSK Group
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 19,334.0 | 11.0 | 19,345.0 |
|
Other Revenue
|
n/a | n/a | n/a |
| Total Revenue | 19,334.0 | 11.0 | 19,345.0 |
|
Cost of Revenue
|
9,398.0 | 6.5 | 9,404.5 |
|
SG&A Expense
|
4,564.0 | 23.7 | 4,587.7 |
|
Depreciation & Amortization
|
33.0 | 0.7 | 33.7 |
|
Research & Development
|
1,133.0 | 57.2 | 1,190.2 |
|
Interest Expense
|
n/a | n/a | n/a |
|
Other Operating Expense
|
n/a | n/a | n/a |
|
Unusual Expense (Income)
|
1,036.0 | 1.7 | 1,037.7 |
| Total Expenses | 16,164.0 | 88.2 | 16,252.2 |
|
Operating Income
|
3,170.0 | -77.2 | 3,092.8 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-185.0 | -3.0 | -188.0 |
|
Other, Net
|
n/a | -1.7 | -1.7 |
| Income Before Taxes | 2,985.0 | -69.3 | 2,915.7 |
| Income Taxes | 69.0 | n/a | 69.0 |
| Income After Taxes | 2,916.0 | -95.9 | 2,820.1 |
| Minority Interest (IS) | -1.0 | n/a | -1.0 |
| Equity in Affiliates | -58.0 | n/a | -58.0 |
|
Net Income - Excl. Xord. Items
|
2,857.0 | -95.9 | 2,761.1 |
|
Net Income - Incl. Xord. Items
|
2,857.0 | -95.9 | 2,761.1 |
| Preferred Dividends | n/a | -2.8 | -2.8 |
|
Income Avail. to Common
|
2,857.0 | -98.7 | 2,758.3 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
880.0 | 164.2 | 1,044.2 |
|
Basic EPS - Excl. Xord. Items
|
3.23 | -0.48 | 2.64 |
|
Basic EPS - Incl. Xord. Items
|
3.23 | -0.48 | 2.64 |
| Full Dilution Adjustment | n/a | n/a | n/a |
| Fully Diluted Shares Outstanding | 882.0 | 164.2 | 1,046.2 |
|
F.D. EPS - Excl. Xord. Items
|
3.22 | -0.48 | 2.64 |
|
F.D. EPS - Incl. Xord. Items
|
3.22 | -0.48 | 2.64 |
| Dividends Per Common Share | 0.98 | n/a | 0.98 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
1,062.0 | 88.2 | 1,150.2 |
|
ST Investments
|
38.0 | n/a | 38.0 |
|
Accounts Receivable
|
6,056.0 | 1.0 | 6,057.0 |
|
Inventory
|
5,332.0 | n/a | 5,332.0 |
|
Prepayments and Advances
|
n/a | 2.8 | 2.8 |
|
Other Current Assets
|
2,517.0 | n/a | 2,517.0 |
|
Current Assets
|
14,967.0 | 60.3 | 15,027.3 |
|
Accum D&A
|
n/a | n/a | n/a |
|
PPE, Net
|
6,083.0 | 80.9 | 6,163.9 |
| Goodwill & Intangibles | 28,213.0 | 11.0 | 28,224.0 |
| Long Term Investments | 1,044.0 | n/a | 1,044.0 |
| Other Assets | n/a | n/a | n/a |
|
Other LT Assets
|
163.0 | 3.8 | 166.8 |
| Total Assets | 50,470.0 | 187.8 | 50,657.8 |
| Liabilities | |||
| Accounts Payable | n/a | n/a | n/a |
| Payable/Accrued | 3,199.0 | 4.8 | 3,203.8 |
| Accrued Expenses | n/a | 4.7 | 4.7 |
|
ST Debt
|
3,834.0 | n/a | 3,834.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
531.0 | 1.3 | 532.3 |
| Other (Current) Liabilities | 6,063.0 | 3.5 | 6,066.5 |
|
Current Liab.
|
13,627.0 | 14.4 | 13,641.4 |
|
LT Debt
|
10,157.0 | 12.2 | 10,169.2 |
| Capitalized Lease Obligations | n/a | 74.5 | 74.5 |
|
Total LT Debt
|
10,157.0 | 89.2 | 10,246.2 |
| Minority Interest (BS) | 149.0 | n/a | 149.0 |
| Deferred Taxes | 2,210.0 | n/a | 2,210.0 |
|
Other LT Liab.
|
1,276.0 | 4.0 | 1,280.0 |
|
Total Liabilities
|
27,419.0 | 146.6 | 27,565.6 |
| Shareholders Equity | |||
| Common Stock | n/a | 0.0 | 0.0 |
| Additional Paid in Capital | n/a | 1,108.6 | 1,108.6 |
| Retained Earnings | n/a | -1,079.8 | -1,079.8 |
| Treasure Stock | n/a | -23.1 | -23.1 |
| Other Equity | 23,051.0 | 4.7 | 23,055.7 |
|
Total Equity
|
23,051.0 | 44.8 | 23,095.8 |
|
Total Liab. & Equity
|
50,470.0 | 191.4 | 50,661.4 |
|
Shares Outstanding
|
942.0 | 146.1 | 1,088.1 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 2,858.0 | -95.9 | 2,762.1 |
| CF Depreciation | -1,227.0 | 10.0 | -1,217.0 |
| CF Amortization | n/a | 0.7 | 0.7 |
| CF Deferred Taxes | 396.0 | n/a | 396.0 |
| Other Non-Cash Items | 1,624.0 | 14.0 | 1,638.0 |
| Change in Working Capital | 339.0 | -4.9 | 334.1 |
| Total Cash From Operating Activities | 3,990.0 | -76.1 | 3,913.9 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | 1,196.0 | -0.8 | 1,195.2 |
| Other Investing Cash Flows | -8,315.0 | -0.0 | -8,315.0 |
| Total Cash From Investing Activities | -7,119.0 | -0.8 | -7,119.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | 1,016.0 | n/a | 1,016.0 |
| Purchase Or Sale of Stock | 1,158.0 | 58.0 | 1,216.0 |
| Purchase and Retirement of Debt | -32.0 | -13.7 | -45.7 |
| Other Financing Cash Flow | 1,351.0 | n/a | 1,351.0 |
| Total Cash From Financing Activities | 3,493.0 | 44.3 | 3,537.3 |
| Exchange Rate Effects | -23.0 | 1.0 | -22.0 |
| Net Change in Cash | 341.0 | -31.7 | 309.3 |
| Cash Interest Paid | n/a | 9.5 | 9.5 |